ライフサイエンスコーパス: blood loss

1 esthesiologists class and surgical severity (blood loss).

2 ate in prolonged field care following severe blood loss.

3 t difference in the amount of intraoperative blood loss.

4 cers, and a higher incidence of fecal occult blood loss.

5 logical stress, such as infection or chronic blood loss.

6 eal phase deficiency, long menses, and heavy blood loss.

7 terature, few focus on directly quantitating blood loss.

8 o fibrin to stabilize blood clots and reduce blood loss.

9 Primary endpoint was intraoperative blood loss.

10 preoperative diagnosis, operative time, and blood loss.

11 competence and influences the perioperative blood loss.

12 Surgery lasted 400 minutes with 400 mL of blood loss.

13 n failure and death, despite the stemming of blood loss.

14 were higher grade, stage, and intraoperative blood loss.

15 to short coat hair, disease transmission and blood loss.

16 orrhage and exhibit a delay in recovery from blood loss.

17 reased risk of transfusion despite increased blood loss.

18 r organ transplantations to reduce excessive blood loss.

19 isol, albumin, age, duration of surgery, and blood loss.

20 P < 0.05) and had reduced risk of excessive blood loss.

21 der patients with significant intraoperative blood loss.

22 for older patients with significant surgical blood loss.

23 ically ill patients, due to inflammation and blood loss.

24 surgical injury and may result in increased blood loss.

25 There was no difference in blood loss.

26 surgical injury and may result in increased blood loss.

27 , culminating in a physical barrier to limit blood loss.

28 nia, and platelet consumption due to massive blood loss.

29 ncreased in relationship to the magnitude of blood loss.

30 ations and postoperative 24-hour mediastinal blood loss.

31 ay 1, which was used as a proxy for maternal blood loss.

32 pathological defective absorption or chronic blood loss.

33 traoperative bleeding reduces intraoperative blood loss.

34 roup showed longer operative time and higher blood losses.

35 low was preserved during moderate and severe blood losses.

36 Body mass index was 29 (23-43), estimated blood loss 1.0 L (0-23), and operating room time 160 min

37 The incidence of high blood loss (13.3%), conversion (2.2%), and leaks (5.8%)

38 s (402 vs 322 minutes; P < 0.001), operative blood loss (18 vs 14 packed red blood cell units; P = 0.

39 Median blood loss [200 mL (60-400) vs 300 mL (150-500), P = 0.0

40 Lower blood loss (250 vs 400 mL, P = 0.001), less overall morb

41 mpared with ovulatory cycles (geometric mean blood loss: 29.6 vs. 47.2 mL; P = 0.07).

42 decreases over time were observed in median blood loss (300, 250, 200 mL, P < 0.001), transfusion ra

43 The conversion rate was 11% (n = 12), median blood loss 350 mL (IQR = 200-700), and operative time 37

44 P < 0.01) and showed an increased amount of blood loss (350 [20-1500] mL vs 100 [10-1100] mL, P = 0.

45 RAMIE resulted in less median blood loss (400 vs 568 mL, P <0.001), a lower percentage

46 operative time (263 minutes), intraoperative blood loss (425 mL), median length of stay (9.5 days), o

47 blood loss was less in the diet group: mean blood loss 452 vs 863 mL (P = 0.021).

48 rm ischemia time 180 (90) seconds, estimated blood loss 50 (32) mL, and length of stay 3 (1) days.

49 (50.8 vs 77.3 minutes), lower intraoperative blood loss (52.7 vs 97.8 mL), diminished pain intensity

50 ger operative times (393 vs 300 minutes) and blood loss (600 vs 400 mL), but significantly lower oper

51 A significantly higher mean 12-h chest tube blood loss (655 +/- 580 ml vs. 503 +/- 378 ml; p = 0.050

52 ion (154, 58%), time to discharge (96, 36%), blood loss (85, 32%), operative time (79, 30%) and blood

53 utes, BR: 282 minutes; P = .52), but a lower blood loss (A/R: 300 mL, BR: 500 mL; P < .01) and a shor

54 he possible role of other external injuries, blood loss, acute stress disorder and the potential for

55 Blood loss after a 4-mm tail snip was measured.

56 important cells in the primary prevention of blood loss after injury.

57 Although blood loss after tail tip amputation was similar in HRG-

58 Blood loss after tail transection significantly decrease

59 e variants shortened clotting times, reduced blood loss after tail-clip assay, and reinstalled clot f

60 adherent, shear-resistant thrombi to prevent blood loss after vessel injury.

61 omy was associated with lower intraoperative blood loss, although the clinical significance of this f

62 The mean blood loss among current smokers was significantly highe

63 loss of 43.26 +/- 31.5 mL, whereas the mean blood loss among patients that did not use this medicati

64 ic aorta (Zone 1) can limit subdiaphragmatic blood loss and allow for IV fluid resuscitation when int

65 human PEVs would promote hemostasis, reduce blood loss and attenuate the progression to hemorrhagic

66 concentrations and subsequent total reported blood loss and bleeding length by weighted linear mixed-

67 PN-1-/- mice displayed significantly reduced blood loss and bleeding time compared with F8-/-mice.

68 thetic management has reduced intraoperative blood loss and blood product transfusions.

69 Statistical improvements in estimated blood loss and conversions to open surgery occurred afte

70 lay to recognize bleeding may lead to a high blood loss and increases the risk of death.

71 ng at wound sites is critical for preventing blood loss and invasion by microorganisms in multicellul

72 gelatinous matter formed upon injury to stop blood loss and is later destroyed by fibrinolysis, an en

73 After training, perioperative blood loss and length of stay improved, while complicati

74 ative time and cost, but decreases estimated blood loss and length of stay.

75 During the operation, there was less blood loss and less need for a wound drain in the laparo

76 ch was an independent predictor of decreased blood loss and less transfusions than the open approach.

77 More blood loss and longer hospital stays occurred in the fus

78 ber of patients with 500 mL or more surgical blood loss and lowest risk-adjusted 30-day surgical mort

79 aroscopic right hepatectomy allowing for low blood loss and morbidity.

80 oietic recovery from hemolytic anemia, acute blood loss and myeloablation.

81 SVC in the event of a laceration, preventing blood loss and offering a more controlled surgical field

82 A significant decrease in blood loss and operative time was noted.

83 creatic texture, duct diameter, BMI) without blood loss and pathology, and was successfully validated

84 to open liver resection, including decreased blood loss and postoperative complications and a shorter

85 nal lymphadenectomy and measures to minimize blood loss and postoperative morbidity for maximal survi

86 LDP has lower blood loss and reduced length of hospital stay.

87 s a potential approach to decrease operative blood loss and shorten recovery.

88 ncreaticoduodenectomy (OPD), including lower blood loss and shorter hospital stay.

89 drogels yield significantly lower amounts of blood loss and shorter times to hemostasis compared with

90 sis showed a significant association between blood loss and technique used (coefficient: 66.3, 95% co

91 ating iron mobilization from the liver after blood loss and that HIF regulates NCOA4 expression in ce

92 ope, iron deficiency is more often caused by blood loss and the cause must be sought and dealt with.

93 ntation (OLT) has been associated with major blood loss and the need for blood product transfusions.

94 ual and may enable earlier detection of both blood loss and the response it elicits.

95 to each other and the vessel wall to prevent blood loss and to facilitate wound repair.

96 of Caesarian section to minimize postpartum blood loss and to further delineate the mass with imagin

97 Blood loss and transfusion are frequent among patients u

98 for oncologic outcomes and due to decreased blood loss and transfusion may have improved survival.

99 e offers the potential benefits of decreased blood loss and transfusion rates, reduced analgesic requ

100 fficacy of tranexamic acid (TXA) in reducing blood loss and transfusion requirements during liver tra

101 tomy (PD) can be associated with significant blood loss and transfusion requirements, with potential

102 Blood loss and transfusions are known to significantly i

103 perative hypotension as a means for reducing blood loss and transfusions.

104 ost-operatively would then lead to increased blood loss and transfusions.We examined 105 consecutive

105 al pressure of 35-40 mm Hg for 20 mins (~40% blood loss), and animals were left in shock for 60 mins.

106 nd-assisted or open procedure, and estimated blood loss), and postoperative variables (transfusion re

107 l frame, longer anesthetic duration, greater blood loss, and a lower percentage of colloid in the non

108 Operative time, conversion to open, blood loss, and clinically relevant postoperative pancre

109 patient education level, type of operation, blood loss, and complications.

110 ions, harvested lymph nodes, operative time, blood loss, and hospital stay were compared using weight

111 nction was evident, with </=135-fold reduced blood loss, and improved buccal bleeding times decreased

112 risk factors for transfusion include anemia, blood loss, and inappropriate transfusion decisions.

113 ry correlates closely with the presentation, blood loss, and need for cardiopulmonary bypass to facil

114 The mean operative time, mean blood loss, and rate of conversion to the open procedure

115 gement, to minimize iatrogenic (unnecessary) blood loss, and to harness and optimize patient-specific

116 n, length of surgery, vasoactive drugs used, blood loss, and transfusion) were collected prospectivel

117 tinal diseases, evidence of gastrointestinal blood loss, and unexplained iron-deficiency anemia), and

118 s is stimulated, for example following acute blood loss, appropriately enhancing cellular iron export

119 Anemia and operative blood loss are common in the elderly, but evidence is la

120 (POPF) after pancreatoduodenectomy, without blood loss as a predictor.

121 benefits of earlier convalescence, decreased blood loss, as well as decreased pain.

122 e bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessme

123 of blood in anticipation of the significant blood loss associated with parturition.

124 Even with the best possible management, the blood loss associated with placenta accreta can resemble

125 sured blood loss >/= 1,000 ml; mean measured blood loss at 1, 2, and 24 h after delivery; death; requ

126 le in hemostasis, that is, the prevention of blood loss at sites of mechanical vessel injury.

127 The primary safety outcome was measured blood loss between study drug administration and transfe

128 For more safety and longer survival, blood loss, bile leakage, and morbidity should be reduce

129 Because of covariation, blood loss, blood transfusion, and complications were te

130 LDP had lower blood loss by 355 mL (P < 0.001) and hospital length of

131 blood platelets in hemostasis is to prevent blood loss by stable thrombus formation.

132 ; 95% CI, 0.19-1.75; P = .02), and estimated blood loss (coefficient, 0.02; 95% CI, 0.01-0.03; P = .0

133 telets also showed a significant increase in blood loss compared with mice injected with wild-type pl

134 Minimizing blood loss contributes to fewer intraoperative transfusi

135 Secondary endpoints were blood loss, conversion rate, postoperative recovery, mor

136 on of surgery, warm ischemia time, operative blood loss, conversion, and complication rates were not

137 escribes the steps required to achieve a low-blood-loss decerebration in the mouse and approaches for

138 r initiation of training, mean perioperative blood loss decreased (-255 mL, P<0.001), OT increased (+

139 ery of operative blood transfusions to treat blood loss depend not only on the patient and surgery ch

140 Although the estimated blood loss differed significantly between groups (237 mL

141 nt modifying factor relationships (estimated blood loss, duration of surgery, hepatic vascular occlus

142 crystalloid, colloid, blood products, urine, blood loss, duration, and approach.

143 Pringle maneuver is widely used to minimize blood loss during hepatectomy, without an established ti

144 Moreover, 2 reduced blood loss during liver hepatectomy, while 1 and aprotin

145 Inflow occlusion reduces blood loss during liver transection in selected patients

146 c that has been used successfully to prevent blood loss during major surgery.

147 n used as antifibrinolytic agents to prevent blood loss during major surgery/trauma.

148 udy support previous papers and confirm that blood loss during periodontal surgery is minimal.

149 esults support the hypothesis that degree of blood loss during surgery for colon cancer is a factor t

150 udy tested the hypothesis that the amount of blood loss during surgery for colonic cancer influences

151 The perioperative blood loss during surgery for colorectal cancer relates

152 Blood loss during surgery is an important operative comp

153 fibrinolytic drugs are widely used to reduce blood loss during surgery.

154 Median blood loss during the operation was significantly less (

155 Estimated blood loss (EBL) was discretized (0 to 300, 301 to 750,

156 Blood loss, expressed as a percentage of total blood vol

157 The type of surgery performed, overall blood loss, extent of lymphadenectomy, rate of resection

158 enefits to robotic surgery include decreased blood loss, fewer perioperative complications, and decre

159 ng meticulous surgical technique, minimizing blood loss, fluid management can be guided by transesoph

160 ime, islet equivalent (IE) counts, estimated blood loss, fluid resuscitation, and blood transfusions.

161 ts demonstrated a 24% reduction in abdominal blood loss following liver trauma in the PEVs group when

162 nt and at least a 50% reduction in menstrual blood loss from baseline to the final month; missing dat

163 ignificantly increased bleeding duration and blood loss from pretreatment (experiment 1, 12 subjects)

164 ism in mice without significantly increasing blood loss from surgically challenged animals.

165 The average blood loss from the treated femoral artery during the fi

166 evalence of maternal haemorrhage, defined as blood loss greater than or equal to 1) 500 ml or 2) 1000

167 Secondary outcomes included measured blood loss >/= 1,000 ml; mean measured blood loss at 1,

168 ome of interest was PPH, defined as measured blood loss >/= 500 ml within 24 h of delivery.

169 The prevalence of severe PPH (blood loss >/=1000 ml) was highest in Africa at 5.1% and

170 prevalence of postpartum haemorrhage (PPH) (blood loss >/=500 ml) ranged from 7.2% in Oceania to 25.

171 was PPH, using multiple definitions; (PPH-1) blood loss >/=500 mL; (PPH-2) PPH-1 plus women who recei

172 Blood loss >2 L (Odd ratio: 11.808, p = 0.0244) was an i

173 endent risk factor for 30-day mortality, and blood loss >2 L (Odd ratio: 4.046, p = 0.0271) and bile

174 lesions was significative in both groups and blood loss >350 cc in LLS.

175 , 95%CI 1.01-1.14, p = 0.046), and estimated blood loss >=2L (OR 11.89, 95%CI 2.64-53.61, p = 0.001)

176 7, 95%CI 1.56-5.26, p = 0.001) and estimated blood loss >=2L (OR 3.52, 95%CI 1.25-9.90, p = 0.017) we

177 y, 30 of 126 women (24%) experienced massive blood loss (>2000 mL).

178 mortality and morbidity due to decreases in blood loss>2L and bile leakage.

179 ed robotic-operative field coupled with less blood loss has paralleled greater understanding of the p

180 rates for patients with significant surgical blood loss have lower adjusted 30-day mortality for thes

181 Average operative time, blood loss, ICU stay and overall length of stay was just

182 functional iron deficiency in CKD, including blood losses, impaired iron absorption, and chronic infl

183 Miropin also acted in vivo by reducing blood loss in a mice tail bleeding assay.

184 f 1.5 mg/kg and higher significantly reduced blood loss in a tail-clip-bleeding model using FVIII-def

185 ional issues necessary to respond to massive blood loss in an immediate and sustained manner.

186 ement in clot formation over protection from blood loss in hemophilia.

187 their use has been restricted to preventing blood loss in hemostatic dysregulation because of poor e

188 nditions, while it only marginally increased blood loss in mice.

189 The primary outcome was blood loss in milliliters between intervention (ie, afte

190 o close rapidly after birth and thus prevent blood loss in newborns.

191 was associated with decreased intraoperative blood loss in patients undergoing liver surgery.

192 The mean (SD) estimated blood loss in patients with or without embolization was

193 The ability to prevent blood loss in response to injury is a conserved function

194 For the primary outcome, median blood loss in the fibrinogen group was 50 mL (interquart

195 hysiologically-benign approach to mitigating blood loss in tissue-injury scenarios.

196 ve oxygenation: OR, 0.86, 95% CI, 0.80-0.93; blood loss [in milliliters]: OR, 1.17, 95% CI, 1.05-1.30

197 ment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500

198 re relevant to arterial thrombosis, with 15 (blood loss increase of 2-fold relative to the ED80 value

199 ted that region and method of measurement of blood loss influenced prevalence estimates for both PPH

200 s (longer in the RS group), and in estimated blood loss, intraoperative transfusion, length of stay,

201 g; however, sometimes, detecting the site of blood loss is challenging.

202 Clamping of vessels to prevent blood loss is integral to liver surgery, but the resulti

203 understanding of the homeostatic response to blood loss is limited, in part by coarse interpretation

204 Blood loss is prevented by the multidomain glycoprotein

205 versions, operative and warm ischemia times, blood loss, length of hospital stay, pain score, convale

206 High blood loss, long operative time, and arterial resections

207 in terms of shorter surgery duration, lower blood loss, lower postoperative pain, faster recovery, i

208 [OR] 1.01 [95% CI 0.98-1.04], p = 0.393) or blood loss (<500 ml: nitroglycerin, 238 [44.3%], versus

209 tus, tumors >25 mm, excessive intraoperative blood loss, manual anastomosis, and prolonged perineal o

210 uding low-volume centers, age, and increased blood loss, may be used to improve outcomes.

211 interval (CI) 17.5-133.3, P = 0.01], reduced blood loss (mean difference = -181 mL, 95% CI -355-(-7.7

212 , respectively; P = .02), and more estimated blood loss (mean, 134 vs. 67 mL, respectively; P = .01).

213 5 women exposed to prophylactic oxytocin had blood loss measured after vaginal delivery at five hospi

214 rative parameters (operation time [OP] time, blood loss, method of pancreas transection, additional o

215 compared to clopidogrel in the rat surgical blood loss model.

216 me to end of resection phase, intraoperative blood loss, number of transfused units of blood, and pos

217 eater when there is substantial (500-999 mL) blood loss (odds ratio: 0.35, 95% CI: 0.22-0.56 for hema

218 ative time was 318 minutes with an estimated blood loss of 125 mL.

219 Blood loss of 250 mL or more during surgery, male gender

220 rative time of 417 minutes, median estimated blood loss of 250 mL, a conversion rate of 3.3%, 90-day

221 Additional blood loss of 300 mL or greater after treatment occurred

222 Additional blood loss of 300 mL or greater after treatment occurred

223 active bleeding within 20 min and additional blood loss of 300 mL or more after treatment.

224 g aspirin (acetylsalicylic acid) showed mean blood loss of 43.26 +/- 31.5 mL, whereas the mean blood

225 The primary end point was menstrual blood loss of less than 80 ml during the final month of

226 odds ratio: 1.81 (1.07-3.07), P = 0.022] and blood loss of more than 500 mL [odds ratio: 1.61 (1.01-2

227 as to elucidate the impact of intraoperative blood loss on outcomes following pancreatoduodenectomy (

228 The negative impact of intraoperative blood loss on outcomes in PD has long been suspected but

229 Blood loss, one of the predictors of the original-FRS, w

230 We use this assay to show that blood loss or EPO administration increases serum ERFE co

231 ac surgery if there is substantial operative blood loss or low preoperative hematocrit levels (<24%).

232 llstone characteristics, local inflammation, blood loss, or length of stay.

233 spleen after EMH induction by myeloablation, blood loss, or pregnancy.

234 gnancy, procedure, surgery length, operative blood loss, or transfusion requirements, but was positiv

235 n transection model resulted in the greatest blood loss (P < .01), with a mean (SD) TBV loss of 27.9%

236 s, intended MIDP was associated with reduced blood loss (P = .006) and length of stay (P = .04).

237 h nodes (P = 0.032), and less intraoperative blood loss (P = 0.017) than with the multiple-incision a

238 cant improvement was observed with regard to blood loss, pain, prolapse, and problems with defecation

239 re, pancreatic duct diameter, intraoperative blood loss, pathologic findings of disease, and intraope

240 The primary outcome was the intraoperative blood loss per joint.

241 negative impact of obesity on intraoperative blood loss, perioperative mortality, and reoperation rat

242 Interestingly, tail blood loss progressively decreased at doses greater than

243 of clot failures correlated positively with blood loss (R = 0.81, p = 0.014) and negatively with sur

244 the two groups experienced similar amount of blood loss, rate of blood transfusions, overall and majo

245 The tail bleeding time and blood loss remained unaltered, indicating normal hemosta

246 tpancreatectomy hemorrhage (PPH), bile leak, blood loss, reoperation, readmission, oncologic outcomes

247 Recovery from blood loss requires a greatly enhanced supply of iron to

248 (1) To measure the incidence of bleeding (blood loss requiring transfusion or intracranial hemorrh

249 dently and completely corrected increases in blood loss resulting from ATIII-dependent anticoagulatio

250 versions (right: 14 [13%] and left: 3 [6%]), blood loss (right: 550 mL [IQR, 350-1150 mL] and left: 3

251 s, hospital course (e.g., lowest hematocrit, blood loss), severity of illness (e.g., Sequential Organ

252 the implantation of the bone implants, less blood loss, shorter operation time and reduced radiation

253 Increasing blood loss significantly correlated with poor perioperat

254 t strategies geared toward reducing surgical blood loss such as autologous transfusion techniques and

255 Timely detection of anemia prior to high-blood loss surgeries can allow clinicians to manage it a

256 gical approach, length of surgery, estimated blood loss, surgical morbidity, length of ICU stay, tota

257 There were no differences in terms of blood loss, surgical times, postoperative complications,

258 All high-titer type 1 MAbs produced blood loss that was significantly greater than control m

259 ce, whereas all non-inhibitory MAbs produced blood loss that was similar to control.

260 h fibrin sealants are considered to minimize blood loss, this is not widely adopted because of its hi

261 ve and postoperative outcomes as measured by blood loss, transfusion rate, R0 negative margin rate, p

262 s BN increased operative duration, estimated blood loss, transfusions, intravenous fluid, and hospita

263 dynamics of the human response to controlled blood loss using these clinical measurements of single-r

264 for older surgical patients with significant blood loss varied from 10% to 92%.

265 and the operation duration did not relate to blood-loss volume.

266 Median blood loss was 100 mL (50-700) and transfusion rate was

267 and blinded evaluation of the perioperative blood loss was 2.2 (range 0.5 to 5.0) versus 1.4 (range

268 standard deviation [SD]) procedure estimated blood loss was 260 mL (+/-100), mean (SD) resected graft

269 Mean measured blood loss was 341.5 ml (standard deviation [SD] 206.2)

270 inutes (IQR, 270-391 minutes) and the median blood loss was 500 mL (IQR, 250-925 mL).

271 ients aged 65 years or older whose estimated blood loss was 500 mL or greater in 122 Veterans Affairs

272 During total hepatectomy, median blood loss was 500 mL, and no patient required total cav

273 In the LLS group only, blood loss was a risk factor, whereas the Pringle maneuv

274 perative time was 190 min and mean estimated blood loss was equal to 55 ml.

275 Estimated blood loss was higher and operative times were longer du

276 Operation time was longer and estimated blood loss was higher in the extended resection group th

277 Operative blood loss was less after MIDP (150 vs 400 mL; P < 0.001

278 Intraoperative blood loss was less in the diet group: mean blood loss 4

279 Operative blood loss was less with laparoscopic surgery compared w

280 p (50 vs 100 mL, P = 0.06), median estimated blood loss was low.

281 .44 minutes (24.06-166.81 minutes)}, whereas blood loss was lower for LPD [MD (CI) -150.99 mL (-168.5

282 g events were increased after challenge, but blood loss was not significantly increased.

283 Blood loss was significantly associated with an increase

284 The blood loss was significantly reduced in the ultrasonic g

285 after which saline in amounts to 2 times the blood loss, was administered over 30 mins.

286 Mean operative time and blood loss were 425 minutes and 232 mL, respectively.

287 (38% [n = 27] vs 8% [n = 11], P < 0.001) and blood loss were lower after training and more pancreatic

288 ng-vascular complications, and perioperative blood loss were not identified as predictors.

289 Sex, age, and intraoperative blood loss were not significantly associated with surviv

290 st-operative hemoglobin values and estimated blood loss were the most significant risk factors for ab

291 Ranges of operative times and estimated blood losses were 83 to 225 minutes and 0 to 115 mL, res

292 Blood losses were determined spectrophotometrically (TT)

293 ters, including operative time and estimated blood loss, were reported between groups.

294 has variably shown increased intraoperative blood loss when compared to hilar controlled procedures.

295 gery was associated with less intraoperative blood loss when compared to the conventional method for

296 closes rapidly at birth, preventing neonatal blood loss, whereas the umbilical vein remains patent lo

297 irmed reductions in index and 90-day LOS and blood loss with similar morbidity between RADP and ODP.

298 punch biopsy models resulted in most of the blood loss within the first 2 minutes, whereas the splee

299 omplications (OR 0.62; P = 0.001), estimated blood loss (WMD -118.9 mL; P < 0.001), and hospital stay

300 , 95% CI = 29-118], but lower intraoperative blood loss (WMD = -385 mL, 95% CI = -616 to -154), less